pentobarbital will reduce the extent or result of theophylline by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.

Too rapid administration may perhaps bring about respiratory melancholy, laryngospasm, apnea, or vasodilation with fall in blood pressure level

Contraindicated (one)pentobarbital decreases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can decrease panobinostat stages by ~70% and bring about remedy failure.

Induction of microsomal enzymes by this drug, may well shorten the 50 %-lifetime of doxycycline for as long as two weeks just after barbiturate therapy discontinued; keep an eye on clinical response to doxycycline carefully if both medicines administered concurrently

Watch Carefully (1)pentobarbital will decrease the level or result of tadalafil by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

Just after halting a CYP3A4 inducer, as more info the effects in the inducer drop, the fentanyl plasma focus will increase which could increase or lengthen both equally the therapeutic and adverse results.

Contraindicated (one)pentobarbital will minimize the extent or outcome of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will reduce the extent or effect of paclitaxel by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.

pentobarbital will lessen the level or outcome of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unidentified.

Contraindicated (one)pentobarbital will minimize the level or influence of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Check Intently (1)pentobarbital will reduce the level or result of glecaprevir/pibrentasvir by impacting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will reduce the level or result of ketoconazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.

pentobarbital will decrease the extent or effect of piroxicam by impacting hepatic enzyme CYP2C9/ten metabolism. Slight/Importance Unfamiliar.

Contraindicated (one)pentobarbital will reduce the extent or outcome of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with sturdy CYP3A4 inducers may result in reduced serum concentrations and loss of antimalarial efficacy